|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
October 21, 2005Biogen confident on Tysabri - Mullen expects FDA to rule by June 30 on restarting salesCLICK FOR MORE - The Boston GlobeBiogen Idec Inc.'s chief executive, James C. Mullen, said he expects the Food and Drug Administration to rule by June 30, 2006, on the company's application to restart sales of its multiple sclerosis drug Tysabri. In an interview with Boston Globe editors and reporters, Mullen spoke with confidence about Tysabri's return, at one point speculating about ''when it comes back." |